• In August 2026, Inspire Medical Systems reported second-quarter 2026 results showing sales of US$200.58 million, down from US$217.09 million a year earlier, but swinging from a US$3.59 million net loss to a US$0.314 million net profit with basic and diluted earnings per share of US$0.01 from continuing operations.
• For the first half of 2026, sales softened and the company reported a higher net loss than a year ago, yet management raised full-year 2026 revenue guidance to US$835 million–US$875 million and updated diluted per-share guidance to a range spanning a US$0.42 loss to US$0.17 in earnings, pointing to improved confidence in the year ahead.
• We’ll now examine how this shift to quarterly profitability, alongside higher full-year guidance, reshapes Inspire Medical Systems’ investment narrative.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Inspire Medical Systems Investment Narrative Recap

To own Inspire Medical Systems, you need to believe its implant-based approach to obstructive sleep apnea can justify ongoing investment in Inspire V and related digital tools despite execution bumps. The swing to a small quarterly profit and higher 2026 revenue and EPS guidance highlights some operational progress, but it does not remove the near term risk that slower Inspire V rollout, elevated marketing spend, and evolving reimbursement could still pressure margins and dampen confidence in the recovery path.

The clearest link to this earnings report is the updated 2026 outlook, with revenue now guided to US$835 million to US$875 million and diluted EPS in a wide range from a US$0.42 loss to US$0.17 in earnings. Against earlier, much higher guidance, this reset underlines how coding, reimbursement, and Inspire V implementation remain central catalysts that could shift expectations again as investors weigh whether recent quarterly profitability is sustainable or just a temporary blip.

Yet behind this improving headline profit, the real risk investors should be aware of is that slower Inspire V adoption and higher costs could still...

Inspire Medical Systems' narrative projects $987.4 million revenue and $67.1 million earnings by 2029.

Uncover how Inspire Medical Systems' forecasts yield a $52.17 fair value, a 13% downside to its current price.

Exploring Other Perspectives

Before this reset, the most optimistic analysts were modeling about US$1.0 billion of revenue and roughly US$72 million of earnings by 2029, which is far more upbeat than consensus. When you compare that to today’s softer first half and the renewed focus on coding and reimbursement progress, it highlights how different your view might be if you expect Inspire’s device reliance to be a key vulnerability versus a springboard for faster procedure growth once current headwinds clear.

Explore 9 other fair value estimates on Inspire Medical Systems - why the stock might be worth over 4x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Inspire Medical Systems research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Inspire Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inspire Medical Systems' overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.